Accendra Health Inc Dossier - Source-backed chat

Accendra Health Inc

ACHNYSE

SectorHealth Care

IndustryHealth Care Distributors

Beta (adjusted)1.40

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.56Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $43.3M

Enterprise Value $1.8B

Shares Outstanding 76.4M diluted

Moat Rating None

Next Earnings Date29 Oct 2026

Last ex-dividend14 Dec 2021

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Accendra Health Inc. (formerly Owens & Minor, Inc.) has completed its strategic transformation into a pure-play home-based care provider following the divestiture of its Products & Healthcare Services (P&HS) segment in late 2025. Operating through its leading brands, Apria and Byram Healthcare, the company benefits from strong secular tailwinds in home medical equipment, driven by an aging population and rising demand for lower-cost home-based care. However, the company faces near-term headwinds, including a projected 6% revenue decline in 2026 due to the loss of a large commercial payor contract, pricing pressure in its diabetes product line, and elevated leverage (4.9x net leverage as of Dec 31, 2025). While the successful completion of a $1.5 billion balance sheet optimization transaction in mid-2026 has extended debt maturities and stabilized the capital structure, a 'Hold' rating is recommended until top-line stability and margin expansion materialize.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.70

Mean target$4.49

High · most bullish analyst$6.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.7020%

Ongoing pricing pressure in the diabetes segment accelerates as payors shift more patients to the pharmacy channel. The company struggles to replace lost commercial payor revenues, resulting in prolonged top-line deterioration. Stranded costs remain sticky, keeping EBITDA margins depressed near 10% and delaying deleveraging efforts, leaving the stock vulnerable to further downside.

Base CaseCentral scenario

$4.4955%

Matches the consensus mean

Revenue declines by approximately 6% in 2026 due to the loss of the commercial payor contract, with EBITDA margins compressing to 10%-11% due to stranded costs and separation expenses. Growth recovers to approximately 4% in 2027 and 2028 as sleep therapy and other home-care categories expand. Leverage remains elevated in the near term but gradually trends downward as free cash flow improves post-2026.

Bull CaseUpside scenario

$6.0025%

The company successfully executes its cost-reduction program to eliminate stranded costs from the P&HS divestiture, driving EBITDA margins toward the 14%-15% target by 2027. Strong organic growth in sleep therapy, wound care, ostomy, and urology categories offsets payor contract losses, and rapid free cash flow generation is prioritized for debt repayment, bringing net leverage below 3.0x ahead of schedule.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pure-play exposure to the high-growth, high-margin home-based healthcare market.
Strong national scale and established referral networks through trusted brands Apria and Byram Healthcare.
Successful execution of a comprehensive $1.5 billion balance sheet optimization transaction, extending debt maturities and reducing immediate refinancing risks.

Key Investment Risks

High customer concentration, with the top two commercial payors accounting for approximately 37% of 2025 revenue.
Elevated leverage (4.9x net leverage as of Dec 31, 2025) and near-term margin pressure from stranded corporate costs.
Regulatory and reimbursement risks, particularly pricing pressure in the diabetes product line from channel shifts.

Thesis Invalidation Triggers

Loss of another major commercial payor contract.
Failure to achieve projected EBITDA margin expansion to 14%-15% by 2027.
Inability to generate positive free cash flow to fund debt repayment in 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.